Comparison of siRNA-mediated silencing of glycosaminoglycan synthesis genes and enzyme replacement therapy for mucopolysaccharidosis in cell culture studies

Izabela Chmielarz1, Magdalena Gabig-Cimińska1,2, Marcelina Malinowska1, Zyta Banecka-Majkutewicz1, Alicja Węgrzyn1 and Joanna Jakobkiewicz-Banecka1,2

Cytotoxicity of laronidase (Aldurazyme®), employed in enzyme replacement therapy (ERT) for mucopolysaccharidosis type I (MPS I) and various siRNAs, tested previously in studies on substrate reduction therapy (SRT) for mucopolysaccharidoses, was tested. The enzyme did not cause any cytotoxic effects, and the siRNAs did not inhibit growth of most investigated cell lines. However, some cytotoxic effects of some tested siRNAs were observed in one MPS IIIA cell line. The efficacy of a combination of enzyme replacement therapy and siRNA-based substrate deprivation therapy was tested on three MPS I cell lines. Surprisingly, different results were obtained for different cell lines. The decrease of glycosaminoglycan storage in cells treated simultaneously with both methods was: (i) less pronounced than obtained with either of those methods used alone in one cell line, (ii) similar to that observed for enzyme replacement therapy in another cell line, and (iii) stronger than that obtained with either of the methods used alone in the third cell line. Therefore, it appears that the effects of various therapeutic methods may strongly depend on the features of the MPS cell line.

Key words: ERT, MPS, siRNA, SRT

Received: 18 November, 2012; revised: 05 December, 2012; accepted: 12 December, 2012; available on-line: 18 December, 2012

INTRODUCTION

Mucopolysaccharidoses (MPS) are a group of inherited metabolic diseases characterized by accumulation of glycosaminoglycans (GAG) in lysosomes. These usually fatal disorders are caused by mutation in genes coding for enzymes involved in degradation of GAGs (Neufeld & Muenzer, 2001). The activity deficiencies of appropriate lysosomal enzymes result in variable clinical phenotypes which include organomegaly, dysostosis multiplex, decreased growth and respiratory insufficiency, and in some cases the central nervous system (CNS) is also affected (Neufeld & Muenzer, 2001). Mucopolysaccharidoses are divided into seven distinct types, and into 11 subtypes depending on the deficient enzyme or clinical manifestation.

Since 1980 hematopoietic stem cell transplantation (HSCT) has been used as a therapeutic approach in patients with severe MPS I (Peters et al., 1996; de Ru et al., 2011). Beneficial effects may only be achieved in children who have minimal or no symptoms from the CNS and this procedure is associated with a high incidence of graft failure, morbidity and mortality (Peters & Steward, 2003). Enzyme replacement therapy (ERT) is another approved treatment of MPS. ERT is currently available for MPS I, MPS II and MPS VI (Beck, 2010). Introduction of human recombinant laronidase (Aldurazyme®-Genzyme-Sanoﬁ, Cambridge, MA, USA) in 2001 as the first ERT for mucopolysaccharidoses oﬀered hope for patients and their families (Beck, 2010). Significant improvement in respiratory functions, physical capacity and reduction of organomegaly has been achieved (Kakkis et al., 2001; Wraith et al., 2004). However, neurological symptoms cannot be successfully treated due to the insuﬃcient delivery of the enzyme through the blood-brain barrier (BBB) (Beck, 2010). Other therapeutic approaches such as small synthetic chaperones, gene therapy, stop codon read-through strategy, and substrate deprivation therapy (SDT) are under detailed investigation (Jakobkiewicz-Banecka et al., 2007). One of them, SDT based on inhibition of GAG synthesis by genistein, is used in MPS III (Sanfilippo disease) (Piotrowska et al., 2006). Genistein (5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, also known as 4’, 5, 7-trihydroxyisoflavone), an isoflavone able to cross the BBB is reported not only to reduce lysosomal storage, but also shows signiﬁcant improvement in cognitive function and general behavior (Piotrowska et al., 2008).

Recent studies on specific inhibition of GAG synthesis by siRNA (small interfering RNA) have highlighted possible therapeutic applications for MPSs (Kaidonis et al., 2009; Dziedzic et al., 2010). Selective silencing of expression of a particular gene by speciﬁc degradation of corresponding mRNA became a standard laboratory procedure shortly after initial reports (Rana, 2007). RNA interference, first characterized in the nematode Caenorhabditis elegans (Fire et al., 1998), has a potential for treating wide range of diseases. Preclinical trials are being performed for treatment of amyotrophic lateral scle-rosis, age-related macular degeneration, hepatitis B and C, HIV, hepatic cancer and solid tumor cancers (Kim & Rossi, 2007; Snead & Rossi, 2012). However that approach has disadvantages like immune response, oversat-
uration of endogenous pathways and off-targeting (Kim & Rossi, 2007).

The synthesis of glycosaminoglycans is initiated by formation of GAG-protein linked tetrasaccharide, GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser, to the core protein. Two variants of O-xylosyltransferases (XYLT1 and XYL2) are responsible for the initiation step (Uyama et al., 2007). In the next phase two galactose (Gal) residues are attached in reactions catalyzed by β1,4-galactosyltransferase 7 (GALT7) and β1,3-galactosyltransferase 6 (GALT6). β1,3-glucuronosyltransferase (GLCAT1) completes the biosynthesis by transferring a glucuronic acid (GlcA) residue to the linkage trisaccharide (Przydł & Dalen, 2000). After the synthesis of the GAG sugar backbone, the first N-acetylgalactosamine (GalNAc) residue is transferred to the GlcA residue in the linkage region tetrasaccharide by β1,4-N-acetylgalactosaminyltransferase I or II (GALNACTI or GALNACTII) activity, which is the beginning of the chain elongation process. Numerous modifications including sulfation, epimerization, and desulfation lead to production of mature and functional GAG chains (Uyama et al., 2007).

The aims of this study were: first, to determine any possible cytotoxic effects caused by siRNA and ERT; second, to assess the effectiveness of siRNA-mediated silencing of genes coding for enzymes involved in the initial steps of GAG synthesis in comparison with the enzyme replacement therapy for MPS treatment; third, to assess the effectiveness of siRNA-mediated silencing of genes coding for enzymes involved in the initial steps of GAG synthesis in comparison with the enzyme replacement therapy for MPS treatment; third, to combine both approaches for possible better efficiency of treatment.

**MATERIALS AND METHODS**

**Patients’ characteristics.** Skin fibroblast lines were obtained from forearm skin biopsies from mucopolysaccharidosis (MPS) type I, IIIA and IIIB patients and provided by The Children’s Memorial Health Institute (Warsaw, Poland). As a control healthy human dermal fibroblast (HDF) line was purchased from Cascade Biologics (Life Technologies, Carlsbad, CA, USA). Characteristics of MPS patients genotype are presented in Table 1.

**Cell lines and culture conditions.** Fibroblasts were cultured in 75cm² culture flasks in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1x Antibiotic Antimycotic Solution (Sigma, St Louis, MO, USA) at 37°C in a humidified atmosphere of 5% CO₂. Cells were transfected with siRNA oligonucleotide ID#s3880, siRNA ID#s3881) as presented in the work of Dziedzic and coworkers (2012).

**siRNA transfection.** MPS I, IIIA and IIIB cells were seeded in triplicate into 24-well tissue culture plates, 24 h before transfection. Cells were transfected with Transfection Reagent HiPerFect (Qiagen GmbH, Hilden, Germany) and 25 nM siRNAs (Applied Biosystems — Ambion, Austin, TX, USA) according to manufacturer’s instruction. Pre-designed siRNAs against human genes: XYLTI (siRNA ID#112165, siRNA ID#29873), XYLTI2 (siRNA ID#112168, siRNA ID#212974), GALTI (siRNA ID#113729, siRNA ID#111770), GALTI2 (siRNA ID#112321, siRNA ID#112322) were the same as used and described previously by Dziedzic et al., (2010); while CS-GALNACTI (siRNA ID#s31518, siRNA ID#s31519), CS-GALNACTII (siRNA ID#s3880, siRNA ID#s3881) as presented in the work of Dziedzic and coworkers (2012). For further experimental procedures cell cultures were incubated for 24 or 48 h in standard culture conditions.

**Cytotoxicity assay.** The cytotoxicity assay (MTT assay) was conducted according to the method by Mosmann, (1983), with modifications. MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide)( Sigma, St Louis, MO, USA) dissolved at 1 mg/ml in RPMI 1640 medium (Sigma, St Louis, MO, USA) was substituted for culture medium. After 2 hours of incubation at 37°C in humidified atmosphere of 5% CO₂, MTT solution was removed from culture plates and replaced with DMSO (dimethyl sulfoxide, Sigma, St Louis, MO, USA). Plates were incubated for 5 minutes at room temperature to dissolve formazan products. Absorbance was measured at 550 nm using Victor Multilabel Plate Reader (PerkinElmer Inc. - Life Technologies, Wallham, MA, USA). Estimation of siRNA cytotoxic effect was conducted 24 h and 48 h after transfection procedure as described above while determination of laronidase cytotoxicity was carried out 24 h and 48 h after laronidase treatment.

**Measurement of total GAGs level in cells.** Fibroblasts from MPS I patients were seeded on 6-well tissue culture plates and grown for 24 h at 37°C in a humidified atmosphere of 5% CO₂. Cells were transfected with siRNA oligonucleotide ID#19329 (GALT7) and/or treated with laronidase (100 U/l). After 48 h, cells were washed with PBS and harvested using 0.25% trypsin-ethylenediaminetetraacetic acid solution (Sigma, St Louis, MO, USA). The pellet was digested with 0.03% papain solution from papaya latex (Sigma, St Louis, MO, USA) in 0.1 M sodium acetate buffer for 3 h at 65°C. Afterwards, a quantitative dye binding method — Blyscan (Biocolor Ltd, UK) was performed using 1,9-dimethylmethylene blue to measure sulfated GAGs. The amount of total glycosaminoglycans was standardized against DNA content measured spectrophotometrically using PicoGreen dsDNA Quantification Kit (Molecular Probes - Invitrogen, Carlsbad, CA, USA).

| Table 1. Characteristics of genotypes of MPS patients
<table>
<thead>
<tr>
<th>MPS type</th>
<th>MPS subtype</th>
<th>Patient ID</th>
<th>Mutations</th>
<th>Mutations description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPS I</td>
<td>Hurler</td>
<td>20</td>
<td>Q70X/W402X</td>
<td>STOP codon/STOP codon</td>
</tr>
<tr>
<td></td>
<td>Hurler</td>
<td>21</td>
<td>Q70X/Q70X</td>
<td>STOP codon/STOP codon</td>
</tr>
<tr>
<td></td>
<td>Not determined</td>
<td>25</td>
<td>delD349/delD349</td>
<td>deletion/deletion</td>
</tr>
<tr>
<td></td>
<td>Not determined</td>
<td>54</td>
<td>Q70X/IVS7+2T&gt;C</td>
<td>STOP codon/substitution T→C</td>
</tr>
<tr>
<td>MPS III</td>
<td>A</td>
<td>26</td>
<td>R74C/G90R</td>
<td>Non-conservative aa substitution; destabilization of active site</td>
</tr>
<tr>
<td></td>
<td></td>
<td>38</td>
<td>R74C/R74C</td>
<td>Non-conservative aa substitution; destabilization of active site</td>
</tr>
</tbody>
</table>

---

**REFERENCES**

- Chmielarz I. et al., 2012
- Prydz H., Dalen I. 2000
- Dziedzic et al., 2010
- Mann, (1983)
- Uyama et al., 2007
- Przydł P., Dalen I. 2000
**RESULTS**

### siRNAs and laronidase are not cytotoxic to MPS I and MPS III fibroblasts

Although both siRNA treatment and ERT had been tested previously for various therapeutic and biochemical parameters (see Dziedzic et al., 2010; 2012; Kalkis et al., 2001), they were not tested on in different cell lines of MPS patients. On the other hand, such testing may be important in the light of the high variability of MPS (Neufeld & Muenzer, 2001) and possible different reactions of different cell lines, as well as different patients. Therefore, we tested the cytotoxicity of siRNA treatment on several cell lines derived from MPS I, MPS IIIA and MPS IIIB patients, and of the treatment with human recombinant α-1-iduronidase (laronidase, Aldurazyme®), an enzyme that is used in ERT for MPS I.

For testing the cytotoxicity of siRNAs, we used previously described oligonucleotides (Dziedzic et al., 2010; 2012) and treated three MPS I and three MPS III cell lines of human fibroblasts. The experiments were performed for 24 h and 48 h for each cell line. No cytotoxicity was observed for any tested MPS I cell lines and for any tested siRNAs (Fig. 1). Similar results were obtained in experiments with two MPS IIIA and one MPS IIIB cell lines, however, one evident case of cytotoxicity was found in one of the MPS IIIA cell lines (Fig. 2, panel III-B). Moreover, several cases of weak cytotoxic effects were also observed in the same cell line. All these cytotoxic effects occurred after 48 h (Fig. 2). These results indicate that siRNA treatment is generally not cyto-

---

**Figure 1. siRNA has no cytotoxic effect on MPS I cell lines.**

Three lines of fibroblast from MPS I patients (cell line 20 – I; 21 – II; 25 – III) were transfected with the respective siRNAs: **XYLT1** (siRNA ID#112165, siRNA ID#29073), **XYLT2** (siRNA ID#112168, siRNA ID#212974), **GALT1** (B4GALT7) (siRNA ID#19329, siRNA ID#111770), **GALT2** (B3GALT6) (siRNA ID#12321, siRNA ID#122322), **CS-GALNACT1** (siRNA IDs31516, siRNA IDs31519), **CS-GALNACT2** (siRNA IDs3880, siRNA ID#3881). Panel A shows cytotoxicity effect after 24 h from transfection, and panel B after 48 h. For all graphs, values are presented as means of three biological replications with corresponding SD. ‘Ctrl’ represents untreated cells, ‘Mock ctrl’ indicates conditions when only the transfection reagent was used, ‘Positive ctrl’ indicates transfection with siRNA against the GAPDH gene, ‘Negative ctrl’ represents results with AllStars Negative Control siRNA.
toxic for MPS cells, however, sporadic effects may occur in cells of particular patients.

Unlike for the siRNA treatment, no cytotoxic effects occurred in any of the MPS I cell lines treated with laronidase (Fig. 3). These results confirm that ERT for MPS I is a generally safe treatment in regards its cytotoxicity.

Effects of ERT, siRNA and combined treatments on GAG storage in MPS I cells

We aimed to compare the effects of different treatment methods on the reduction of GAG storage in various cell lines of MPS I. Three MPS I cell lines were treated with laronidase, siRNA or their combination for 48 h. In control experiments, no significant effects of ERT, siRNA treatment or both methods used together on GAGs level was observed in wild-type human fibroblasts (results not shown).

As expected, ERT was more effective than siRNA treatment in reduction of GAGs storage in all tested cell lines (Fig. 4). However, different results were obtained for different cell lines when a combination of these two therapeutic approaches was employed. Depending on the cell line the decrease in GAG storage in cells treated simultaneously with both methods was less pronounced than that obtained with either method used alone (Fig. 4A), similar to that observed in ERT (Fig. 4B), or more pronounced than that obtained with either method alone (Fig. 4C). Therefore, it appears that effects of various
therapeutic methods may strongly depend on the cell line studied.

DISCUSSION

Although various therapeutic methods for MPS are currently being considered and tested, none of the available treatments is sufficiently effective to cure those severe diseases (Jakóbkiewicz-Banecka et al., 2007; Beck, 2010). Therefore, there is a need for the development of new therapies or combinations of already known.

In this report we tested two treatment procedures for MPS, ERT and substrate deprivation therapy based on the use of siRNA. In our approach we used several different cell lines derived from patients suffering from MPS I or MPS III. Perhaps surprisingly, we found that neither laronidase (Aldurazyme®) is cytotoxic for any of the MPS I cell lines tested, nor siRNAs are cytotoxic for most of the MPS I and MPS III cell lines tested. However some cytotoxicity of several siRNAs was observed for one MPS IIIA cell line. As this effect was also observed for the Mock control, the cell line sensitivity to the transfection agent rather than siRNA-dependent cytotoxicity should be considered in this case. We assume this could be an important discovery, as it might indicate that a generally safe therapeutic procedure for MPS can cause adverse effects in some patients. The siRNA-sensitive cell line derived from a patient suffering from MPS IIIA (Table 1, patient no. 26). This patient is a complex heterozygote, but one could not predict the unusual reaction to siRNA on the basis of such a genotype. Thus, we as-

Figure 3. Laronidase has no cytotoxic effect on MPS I cell lines.
Four cell lines from MPS I patients (cell lines: 20, 21, 25, 54) were treated with appropriate concentrations of laronidase (IDUA) (10, 50, 100 U/l), and after 24 h (A) or 48 h (B), cytotoxicity was assessed using the MTT assay.

Figure 4. Effects of combined siRNA and laronidase treatment on MPS I cell lines.
Measurement of total GAGs was performed on three MPS I cell lines 48 h after siRNA transfection or/and laronidase (IDUA) treatment, according to procedures described in Methods. The results are presented as the percentage of untreated control ± S.D. Panel A shows results of experiments with cell line 54, panel B, cell line 21; and panel C, cell line 20.
sume that the genetic background of this patient may be responsible for the siRNA sensitivity.

One of the therapeutic approaches that could potentially result in efficacy higher than that achieved in trials performed to date is combination of various treatment procedures. Therefore, we tested the effects of a combination of ERT and treatment with siRNA on GAG storage in three different MPS I cell lines. Surprisingly, the results varied significantly between these cell lines. The combined therapy was either less effective, of similar efficiency or more effective than ERT used alone, depending on the cell line (Fig. 4). Surprisingly, the highest efficacy was observed in the cell line of the genotype Q70X/W402X, i.e. bearing two nonsense mutation in the IDUA gene (Fig. 4C). One might predict that the substrate deprivation therapy with the use of siRNA should be of the highest efficiency in cells containing some residual activity of the deficient enzyme, and of the lowest efficiency in the case of cells unable to produce full-length enzyme. This is clearly not the case. Furthermore, the second cell line characterized by two null mutations responded differentially to the combined therapy (Fig. 4B), and the only cells potentially producing an α-L-iduronidase variant with some residual activity revealed the weakest efficiency in reduction of GAG levels when treated simultaneously with ERT and siRNA (Fig. 4A).

In summary, the results presented in this report indicate that laronidase (Aldurazyme®) and siRNAs do not cause cytotoxicity in most MPS cell lines, however, some cytotoxic effects could occur in particular cell lines. Moreover, the efficacy of a combination of ERT and the use of siRNA depends on specific features of each cell line, thus, the combined therapy might potentially result in various effects in different patients.

Acknowledgments

This work was supported by the Foundation for Polish Science Team Programme co-financed by the EU European Regional Development Fund (grant no. TEAM/2008-2/7).

REFERENCES


